Orthopedics giant Stryker's (NYSE:SYK) impressed Wall Street in the early part of 2014, but this company is looking ahead to more than just the good feelings from its latest earnings report. Stryker is interested in growth -- and it is looking to buy its way to better results by snapping up small and innovative firms that can give it a leg up on its competition.
Stryker made waves last year when it acquired robotic surgery maker MAKO Surgical, and 2014's only brought more of a buying bonanza from this medical device giant. This past week, Stryker hit the headlines again by picking up German surgical tools firm Berchtold Holdings, a move it expects to boost its fast-growing endoscopy division. It's a much smaller deal than the MAKO buy, especially for a company of Stryker's size, with a market cap of more than $30 billion. But the acquisition of Berchtold gives a big boost to one of Stryker's under-the-radar growth drivers in endoscopy and highlights the company's M&A focus, something that's likely to dominate this company's news in the coming year.
Will Stryker's acquisitions drive reward investors, though? Motley Fool contributor Dan Carroll tells you what to expect from this company's latest buy -- and how Stryker's future could help the leading medical device stock surge.
Does your financial future need a booster shot?
Stryker and other top health care stocks have performed admirably in the wake of the recession, but millions of Americans have waited on the sidelines since the market meltdown in 2008 and 2009, too scared to invest and put their money at further risk. Yet those who've stayed out of the market have missed out on huge gains and put their financial futures in jeopardy. In our brand-new special report, "Your Essential Guide to Start Investing Today," The Motley Fool's personal finance experts show you why investing is so important and what you need to do to get started. Click here to get your copy today -- it's absolutely free.
Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.